Imperial Chemical Industries Limited

Ici Pharma

Zeneca Limited

Astrazeneca Ab

Zeneca Pharma S. A.

Other

Astra Zeneca U.k. Limited

Zeneca Pharma

Syngenta Corporation

Jean-marc M. M. Girodeau

Graham C. Crawley

Philip N. Edwards

Astrazeneca Sas

Graham C Crawley

Philip N Edwards

Jean-Marc M Girodeau

Pierre A Bruneau

Patrick Ple

Keith Oldham

Colin J Strawson

Martin P Edwards

Brian S Tait

David C Aldridge

Michael S Large

Thomas G Bird

Derek W Young

William R Pilgrim

George B Hill

Darren Mckerrecher

Jeffrey Philip Poyser

John F Kingston

Annie Hamon

Laurent Francois Andre Hennequin

Jean Bowler

Alasdair T Glen

Christine Marie Paul Lambert

Laurent F A Hennequin

Thomas G Colerick Bird

Christine M P Lambert

Jean-Marc M M Girodeau

The invention concerns the use of a quinazoline derivative of Formula (I) wherein Qincludes a quinazoline ring optionally substituted with a group such as halogeno, trifluoromethyl and cyano, or a group of the formula: Q&#x2014;X&#x2014; wherein Xincludes a direct bond and O and Qincludes aryl, aryl-(1-6C)alkyl, heterocyclyl and heterocyclyl-(1-6C)alkyl; each of Rand Ris hydrogen or (1-6C)alkyl; Z includes O, S and NH; and Qincludes aryl and aryl-(1-3C)alkyl or a pharmaceutically-acceptable salt thereof, in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human. 

Method of producing an antiangiogenic or vascular permeability reducing effect

The invention concerns quinazoline derivatives of Formula (I) wherein Q includes a quinazoline ring optionally substituted with a group such as halogeno, trifluoromethyl and cyano, or a group of the formula: Q &mdash;X &mdash; wherein X includes a direct bond and O and Q includes aryl, aryl-(1-6C)alkyl, heterocyclyl and heterocyclyl-(1-6C)alkyl; each of R and R is hydrogen or (1-6C)alkyl; Z includes O, S and NH; and Q includes aryl and aryl-(1-3C)alkyl or a pharmaceutically-acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the prevention or treatment of T cell mediated diseases or medical conditions in a warm-blooded animal.

Quinazoline derivatives

The invention concerns quinoline derivatives of formula (I) wherein n is 0-3 and each R , which may be the same or different, is a substituent such as halogeno, hydroxy, amino, nitro, trifluoromethyl, trifluoromethoxy, cyano or (1-6C)alkyl, or optionally substituted phenyl, phenoxy, anilino, N-(1-6C)alkylanilino, benzoyl or pyridyloxy; R and R is hydrogen or optionally substituted (1-6C)alkyl, (2-6C)alkenyl or (2-6C)alkynyl; or pharmaceutically-acceptable salts thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the prevention or treatment of T cell mediated diseases or medical conditions

Quinoline derivatives as tyrosine kinase inhibitors

The invention concerns ether derivatives of the formula I

Ether derivatives having 5-lipoxygenase inhibitory activity

The invention concerns a bicyclic heterocyclic derivative of the formula I ##STR1## wherein Q is an optionally substituted 9-membered bicyclic heterocyclic moiety containing 1 or 2 N's and optionally a further N, O or S heteroatom;

Benzoxazolyl derivatives useful as 5-lipoxygenase inhibitors

The invention concerns a heterocyclic cycloalkane of the formula I ##STR1## wherein Q is an optionally substituted 6-membered monocyclic or 10-membered bicyclic heterocyclic moiety containing one or two nitrogen atoms;

Isoquinolyl, quinoxalinyl and quinazolinyl derivatives as inhibitors of

The invention concerns a heterocycle of the formula I ##STR1## wherein Q is an optionally substituted 6-membered monocyclic or 10-membered bicyclic heterocyclic moiety containing one or two nitrogen atoms; A is (1-6C)alkylene, (3-6C)alkenylene, (3-6C)alkynylene or cyclo(3-6C)alkylene; X is oxy, thio, sulphinyl, sulphonyl or imino; Ar is phenylene which may optionally bear one or two substituents or Ar is an optionally substituted 6-membered heterocyclene moiety containing up to three nitrogen atoms; R.sup.1 is hydrogen, (1-6C)alkyl, (3-6C)alkenyl, (3-6C)alkynyl, cyano-(1-4C)alkyl or (2-4C)alkanoyl, or optionally substituted benzoyl; and R.sup.2 and R.sup.3 together form a group of the formula --A.sup.2 --X.sup.2 --A.sup.3 -- which, together with the carbon atom to which A.sup.2 and A.sup.3 are attached, defines a ring having 4 to 7 ring atoms, wherein A.sup.2 and A.sup.3, which may be the same or different, each is (1-4C)alkylene and X.sup.2 is oxy, thio, sulphinyl, sulphonyl or imino; or a pharmaceutically-acceptable salt thereof. The compounds of the invention are inhibitors of the enzyme 5-lipoxygenase.

Isoquinoline derivatives suitable for use in leukotriene mediated disease

The invention concerns a bicyclic heterocyclic compound of the formula I ##STR1## wherein Q is an optionally substituted 10-membered bicyclic heterocyclic moiety containing 1 or 2 N's and a further O or S heteroatom;

Pyridooxazinyl or pyridothiazinyl as inhibitors of leukotrienes

Indole derivatives as 5-lipoxygenase inhibitors

Heterocyclic cycloalkanes

Benzothiaziny derivatives

The invention concerns a heterocyclic derivative of the formula I ##STR1## wherein Q is an optionally substituted quinoxalinyl or a hydrogenated derivative thereof

5-lipoxygenase inhibitors quinoxalinyl derivatives

The invention concerns a heterocyclic cyclic ether of the formula I ##STR1## wherein Q is an optionally substituted 6-membered monocyclic or 10-membered bicyclic heterocyclic moiety containing one or two nitrogen atoms;

Heterocyclic cyclic ethers

The invention concerns a thiazole of the formula I, ##STR1## wherein Q.sup.1 is an optionally substituted 6-membered monocyclic or 10-membered bicyclic heterocyclic moiety containing one or two nitrogen atoms;

Heterocyclic thiazole derivatives and pharmaceutical compositions

Growing community of inventors

Macclesfield, United Kingdom

Graham C Crawley